Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021

b'A replay of the presentation will be available on the Events page of the company website.\nCellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Friday, May 14, 2021

Information

Geotags:

Madison, Wisconsin, Us

Organisation:

CELLECTAR BIOSCIENCES

Summary

Key Points:

b'A replay of the presentation will be available on the Events page of the company website.\nCellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer.
The company is developing proprietary drugs independently and through research and development collaborations.
The company\xe2\x80\x99s core objective is to leverage its proprietary Phospholipid Drug Conjugate\xe2\x84\xa2 (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company\xe2\x80\x99s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.\nThe company\xe2\x80\x99s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.\nFor more information, please visit www.cellectar.com or join the conversation by liking and following us on the company\xe2\x80\x99s social media channels: Twitter , LinkedIn , and Facebook .\n'

FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available for 1x1 meetings at the following upcoming conference:

Oppenheimer Rare & Orphan Disease Summit
Date:	May 21, 2021
Time:	On demand presentation for registered participants
	Available for 1x1 meetings
Webcast:	To register, click on the link HERE

A replay of the presentation will be available on the Events page of the company website.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

Contacts

Investors:
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
[email protected]